Pharma Pulse: Amgen Invests $600M in Innovation Hub, Novartis Collaborates With Argo, and Wegovy Tops Tirzepatide in Heart Outcomes

This episode of Pharma Pulse covers Amgen’s $600 million investment in a new California R&D center, Novartis’s collaboration with Argo Biopharmaceuticals to boost its cardiovascular pipeline, and new data showing Wegovy outperforming tirzepatide in reducing major adverse cardiovascular events.